英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
ceaft查看　ceaft　在百度字典中的解释百度英翻中〔查看〕
ceaft查看　ceaft　在Google字典中的解释Google英翻中〔查看〕
ceaft查看　ceaft　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Tislelizumab plus chemotherapy versus placebo plus . . .
    Tislelizumab plus chemotherapy as a first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma provided superior overall survival with a manageable safety profile versus placebo plus chemotherapy Given that the interim analysis met its superiority boundary for the primary endpoint, as confirmed by the independent data monitoring committee, this Article represents the
  • FDA Approves First-Line Tislelizumab Plus Chemotherapy for . . .
    The FDA has approved tislelizumab-jsgr plus chemotherapy for frontline use in adult patients with advanced esophageal squamous cell carcinoma and PD-L1 expression
  • New First-line Treatment Option for Esophageal Cancer . . .
    The FDA has approved tislelizumab-jsgr with chemotherapy to treat for certain patients with esophageal cell squamous cell carcinoma
  • label - accessdata. fda. gov
    INDICATIONS AND USAGE 1 1 Esophageal Cancer TEVIMBRA, as a single agent, is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor
  • FDA Approves Tislelizumab for Esophageal Squamous Cell Carcinoma
    The U S Food and Drug Administration (FDA) approved tislelizumab-jsgr (Tevimbra) in combination with platinum-based chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 Drugmaker BeiGene announced the approval in a March 4 news release
  • Tislelizumab Combined With Induction Chemotherapy and . . .
    To evaluate the efficacy and safety of adding tislelizumab to induction chemotherapy and concurrent chemoradiotherapy (CRT), with or without maintenance immunotherapy, in patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC)
  • Kato Breaks Down FDA Approval of Tislelizumab in Esophageal . . .
    Tislelizumab is a PD-1 antibody made in China The trial evaluated tislelizumab in combination with platinum-containing chemotherapy regimens The RATIONALE-306 trial aimed to validate the additive effect of tislelizumab to baseline chemotherapy and its role in the first-line treatment of esophageal squamous cell carcinoma
  • FDA Approves Frontline Tislelizumab Chemo in Advanced PD-L1 . . .
    A study of tislelizumab (BGB-A317) in combination with chemotherapy as first line treatment in participants with advanced esophageal squamous cell carcinoma ClinicalTrials gov Updated October 26, 2024
  • BeOne Medicines Tevimbra (Tislelizumab-jsgr) Monograph for . . .
    Tevimbra (tislelizumab-jsgr) is an FDA-approved cancer treatment option for people with esophageal cancer and gastric cancer The treatment can be used in varying doses in two-, three-, or four-week intervals for adults as a first-line or single-agent treatment of unresectable or metastatic esophageal squamous cell carcinoma and in combination with platinum and fluoropyrimidine-based
  • FDA Approves Tislelizumab for Previously Treated Patients . . .
    The FDA is also reviewing biologics license applications for tislelizumab as a first-line treatment of unresectable, recurrent, locally advanced, or metastatic esophageal squamous cell carcinoma and locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma





中文字典-英文字典  2005-2009